|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antigen-specific in vitro expansion of factor VIII-specific regulatory T cells induces tolerance in hemophilia A mice.
|
31609041 |
2020 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hemophilia A is a congenital disorder caused by deficiency or malfunction of coagulation factor (F) VIII.
|
30350119 |
2020 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rurioctacog alfa pegol (Adynovate) is a modified recombinant factor VIII concentrate used for treating hemophilia A. Aiming to improve treatment tailoring on the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) platform for patients of all ages treated with Adynovate, we have developed and evaluated a population pharmacokinetic (PopPK) model.
|
31435896 |
2020 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hemophilia is a rare bleeding disorder caused by a deficiency of the plasma coagulation factors VIII and IX (hemophilia A [HA] and hemophilia B [HB], respectively).
|
31669933 |
2020 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
BAY 81-8973 (Kovaltry<sup>®</sup> ) is a full-length, unmodified recombinant human factor VIII approved in China for prophylaxis and on-demand treatment in patients with haemophilia A.
|
30993836 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activated factor VIII (FVIIIa) mimetic bsAbs aim to enable prophylactic treatment of hemophilia A patients with and without inhibitors.
|
30887655 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hemophilia is a rare inherited disorder associated with abnormal repeated bleeding and debilitating joint pain due to deficiency in coagulating factors VIII and IX.
|
31679381 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rurioctocog alfa (recombinant factor VIII: Advate<sup>®</sup>) is available for the control of bleeding in patients with hemophilia A in Japan.
|
30604312 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Factor VIII replacement is still the standard of care in haemophilia A.
|
31846611 |
2019 |
|
Hemophilia A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the remaining 9504 patients still being followed up, 5748 (60.5%) had haemophilia A, 1300 (13.7%) haemophilia B, 1980 (20.8%) von Willebrand Disease while 476 (5.0%) had another clotting factor deficiency (Factor I, II, V, combined V and VIII, VII, X, XI and XIII).
|
30515664 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
The comprehensive main phase of the pivotal pathfinder 2 trial showed N8-GP dosed every 4 days (Q4D) provided favourable safety and efficacy for preventing bleeds in 175 patients with haemophilia A.
|
30817066 |
2019 |
|
Hemophilia A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hemophilia A (HA), a rare X-linked recessive genetic disorder caused by insufficient blood clotting factor VIII, leaves affected individuals susceptible to spontaneous and traumatic hemorrhage.
|
30700417 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment options exist for patients with severe hemophilia and high titer factor VIII inhibitors but is often inadequate.
|
31688638 |
2019 |
|
Hemophilia A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our report describes the second patient reported to have severe hemophilia due to this mutation and the only case of a factor VIII inhibitor associated with this mutation.
|
30783064 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hemophilia A (HA) is an X-linked hereditary bleeding disorder caused by deficiency of coagulation factor (F) VIII activity.
|
31203578 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Congenital hemophilia A and B are bleeding disorders characterized by deficiency of factors VIII and IX, respectively.
|
31354248 |
2019 |
|
Hemophilia A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The MD analysis is in line with clinical data of patients who had <1% Factor VIII levels (severe hemophilia) with episodic bleeding, and were on more than one treatment.
|
30793713 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Magnetic resonance imaging confirmed intramuscular hematoma and factor VIII assay confirmed hemophilia.
|
31094906 |
2019 |
|
Hemophilia A
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two of these proteins, produced in the liver, factor VIII and factor IX, are deficient or present a functional defect in people with haemophilia.
|
30999657 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Model-based evaluation of low-dose factor VIII prophylaxis in haemophilia A.
|
31050134 |
2019 |
|
Hemophilia A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A.
|
31044485 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fanhdi/Alphanate is a plasma derived factor VIII concentrate used for treating hemophilia A, for which there has not been any dedicated model describing its pharmacokinetics (PK).
|
31115857 |
2019 |
|
Hemophilia A
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Persons with hemophilia have bleeding episodes into the soft tissues and joints, which are treated with self-infusion of factor VIII or IX concentrates.
|
31332444 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
Haemophilia is a hereditary X-linked recessive disorder caused by a deficiency of either clotting factor VIII (haemophilia A) or IX (haemophilia B).
|
30962210 |
2019 |
|
Hemophilia A
|
0.100 |
Biomarker
|
disease |
BEFREE |
The evolving understanding of factor VIII binding sites and implications for the treatment of hemophilia A.
|
29866493 |
2019 |